The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s showing significant promise in clinical trials for treating obesity. Unlike some existing weight loss solutions, retatrutide appears to provide a greater substantial decrease in body size and improve metabolic health, particularl